Detalhe da pesquisa
1.
Adjuvant ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 372(5): 436-46, 2015 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-25495490
2.
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
N Engl J Med
; 371(2): 107-18, 2014 Jul 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24881463
3.
Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial.
Ann Surg Oncol
; 24(2): 398-406, 2017 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-27663567
4.
Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.
Breast Cancer Res
; 18(1): 110, 2016 11 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-27825388
5.
Adjuvant ovarian function suppression and cognitive function in women with breast cancer.
Br J Cancer
; 114(9): 956-64, 2016 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-27092785
6.
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00.
Breast Cancer Res Treat
; 158(2): 323-31, 2016 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-27372069
7.
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Lancet Oncol
; 16(7): 848-58, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26092816
8.
ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer.
Breast Cancer Res Treat
; 154(3): 543-55, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26590813
9.
Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Breast Cancer Res Treat
; 154(2): 275-86, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26493064
10.
CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial.
Breast Cancer Res Treat
; 151(2): 373-84, 2015 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-25935582
11.
Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial.
Lancet Oncol
; 15(2): 156-63, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24439313
12.
Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences.
Breast Cancer Res Treat
; 144(2): 321-9, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24487691
13.
Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial.
Lancet Oncol
; 14(4): 297-305, 2013 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-23491275
14.
Impact of SERM adherence on treatment effect: International Breast Cancer Study Group Trials 13-93 and 14-93.
Breast Cancer Res Treat
; 142(2): 455-9, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24197662
15.
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer.
N Engl J Med
; 361(8): 766-76, 2009 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-19692688
16.
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause.
Breast Cancer Res Treat
; 131(1): 295-306, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-21892704
17.
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.
Lancet Oncol
; 12(12): 1101-8, 2011 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22018631
18.
Interpreting Breast International Group (BIG) 1-98: a randomized, double-blind, phase III trial comparing letrozole and tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor-positive, early breast cancer.
Breast Cancer Res
; 13(3): 209, 2011 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-21635709
19.
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial.
Breast Cancer Res Treat
; 126(1): 221-6, 2011 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-21046229
20.
Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer.
Breast Cancer Res Treat
; 123(1): 303-10, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20195744